```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[H.R. 587 Reported in House (RH)]

                                                  Union Calendar No. 90

104th CONGRESS

  1st Session

                               H. R. 587

                          [Report No. 104-178]

_______________________________________________________________________

                                 A BILL

   To amend title 35, United States Code, with respect to patents on 
                      biotechnological processes.

_______________________________________________________________________

                             July 11, 1995

Committed to the Committee of the Whole House on the State of the Union 
                       and ordered to be printed

                                                  Union Calendar No. 90
104th CONGRESS
  1st Session
                                H. R. 587

                          [Report No. 104-178]

   To amend title 35, United States Code, with respect to patents on 
                      biotechnological processes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 19, 1995

Mr. Moorhead (for himself, Mr.  Boucher, Mr. Sensenbrenner, Mr. Coble, 
Mr. Frank of Massachusetts, Mr. Gallegly, Mr. Goodlatte, Mr. Gekas, Mr. 
  Bono, Mr. Canady of Florida, and Mr. Hoke) introduced the following 
       bill; which was referred to the Committee on the Judiciary

                             July 11, 1995

   Additional sponsors: Mr. Berman, Ms. Danner, Mr. Rohrabacher, Mr. 
     Evans, Mr. Bryant of Texas, Mr. Klug, Mr. McHale, Mr. Fox of 
Pennsylvania, Mr. Royce, Mr. Forbes, Mrs. Meyers of Kansas, Ms. Eshoo, 
  Mr. Blute, Mr. Saxton, Mr. Zimmer, Mr. Fattah, Mr. Conyers, and Mr. 
                                  Reed

                             July 11, 1995

Committed to the Committee of the Whole House on the State of the Union 
                       and ordered to be printed

_______________________________________________________________________

                                 A BILL

 
   To amend title 35, United States Code, with respect to patents on 
                      biotechnological processes.
    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

                    biotechnological process patents

SEC. 101. CONDITIONS FOR PATENTABILITY; NONOBVIOUS SUBJECT MATTER.

    Section 103 of title 35, United States Code, is amended--
            (1) by designating the first paragraph as subsection (a);
            (2) by designating the second paragraph as subsection (c); 
        and
            (3) by inserting after the first paragraph the following:
    ``(b)(1) Notwithstanding subsection (a), and upon timely election 
by the applicant for patent to proceed under this subsection, a 
`biotechnological process' using or resulting in a composition of 
matter that is novel under section 102 and nonobvious under subsection 
(a) of this section shall be considered nonobvious if--
            ``(A) claims to the process and the composition of matter 
        are contained in either the same application for patent or in 
        separate applications having the same effective filing date; 
        and
            ``(B) the composition of matter, and the process at the 
        time it was invented, were owned by the same person or subject 
        to an obligation of assignment to the same person.
    ``(2) A patent issued on a process under paragraph (1)--
            ``(A) shall also contain the claims to the composition of 
        matter used in or made by that process, or
            ``(B) shall, if such composition of matter is claimed in 
        another patent, be set to expire on the same date as such other 
        patent, notwithstanding section 154.
    ``(3) For purposes of paragraph (1), the term `biotechnological 
process' means--
            ``(A) a process of genetically altering or otherwise 
        inducing a single- or multi-celled organism to--
                    ``(i) express an exogenous nucleotide sequence,
                    ``(ii) inhibit, eliminate, augment, or alter 
                expression of an endogenous nucleotide sequence, or
                    ``(iii) express a specific physiological 
                characteristic not naturally associated with said 
                organism;
            ``(B) cell fusion procedures yielding a cell line that 
        expresses a specific protein, such as a monoclonal antibody; 
        and
            ``(C) a method of using a product produced by a process 
        defined by (A) or (B), or a combination of (A) and (B).''.

SEC. 102. PRESUMPTION OF VALIDITY; DEFENSES.

    Section 282 of title 35, United States Code, is amended by 
inserting after the second sentence of the first paragraph the 
following: ``Notwithstanding the preceding sentence, if a claim to a 
composition of matter is held invalid and that claim was the basis of a 
determination of nonobviousness under section 103(b)(1), the process 
shall no longer be considered nonobvious solely on the basis of section 
103(b)(1).''.

SEC. 103. EFFECTIVE DATE.

    The amendments made by section 101 shall apply to any application 
for patent filed on or after the date of enactment of this Act and to 
any application for patent pending on such date of enactment, including 
(in either case) an application for the reissuance of a patent.
```